Business Description
Compare
Compare
Traded in other countries / regions
YP2A.GermanyBLRX.IsraelBLRX.USA IPO Date
2014-06-18Description
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.15 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 42.3 | |||||
| 3-Year EPS without NRI Growth Rate | 43.9 | |||||
| 3-Year FCF Growth Rate | 39.6 | |||||
| 3-Year Book Growth Rate | -34.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 91.17 | |||||
| 9-Day RSI | 84.38 | |||||
| 14-Day RSI | 77.26 | |||||
| 6-1 Month Momentum % | -44.57 | |||||
| 12-1 Month Momentum % | -63.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.87 | |||||
| Quick Ratio | 4.87 | |||||
| Cash Ratio | 4.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -75.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -42.37 | |||||
| ROA % | -32.65 | |||||
| ROIC % | -113.25 | |||||
| ROC (Joel Greenblatt) % | -1057.3 | |||||
| ROCE % | -34.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.87 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| EV-to-EBIT | -0.21 | |||||
| EV-to-Forward-EBIT | -0.16 | |||||
| EV-to-EBITDA | -0.22 | |||||
| EV-to-Forward-EBITDA | -0.16 | |||||
| EV-to-Forward-Revenue | 3.62 | |||||
| EV-to-FCF | -0.19 | |||||
| Price-to-Net-Current-Asset-Value | 1.73 | |||||
| Price-to-Net-Cash | 1.73 | |||||
| Earnings Yield (Greenblatt) % | -476.19 |
How BioLine Rx Ltd (STU:YP2A) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.43 | ||
| Beta | 0.34 | ||
| Volatility % | 68.7 | ||
| 14-Day RSI | 77.26 | ||
| 14-Day ATR (€) | 0.027771 | ||
| 20-Day SMA (€) | 0.55675 | ||
| 12-1 Month Momentum % | -63.04 | ||
| 52-Week Range (€) | 0.488 - 1.88 | ||
| Shares Outstanding (Mil) | 61.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioLine Rx Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioLine Rx Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioLine Rx Ltd Frequently Asked Questions
What is BioLine Rx Ltd(STU:YP2A)'s stock price today?
The current price of STU:YP2A is €0.69. The 52 week high of STU:YP2A is €1.88 and 52 week low is €0.49.
When is next earnings date of BioLine Rx Ltd(STU:YP2A)?
The next earnings date of BioLine Rx Ltd(STU:YP2A) is 2023-05-11 Est..
Does BioLine Rx Ltd(STU:YP2A) pay dividends? If so, how much?
BioLine Rx Ltd(STU:YP2A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
